Skip to main navigation Skip to search Skip to main content

Relationship of Plasma Apolipoprotein C-I Truncation With Risk of Diabetes in the Multi-Ethnic Study of Atherosclerosis and the Actos Now for the Prevention of Diabetes Study

  • Juraj Koska
  • , Yueming Hu
  • , Jeremy Furtado
  • , Dean Billheimer
  • , Dobrin Nedelkov
  • , Dawn Schwenke
  • , Matthew J. Budoff
  • , Alain G. Bertoni
  • , Robyn L. McClelland
  • , Peter D. Reaven

Research output: Contribution to journalArticlepeer-review

Abstract

Higher truncated-to-native apolipoprotein (apo) C-I proteoform ratios (C-I0/C-I) are associated with favorable cardiometabolic risk profiles, but their relationship with longitudinal changes in insulin resistance (IR) and incident diabetes is unknown. RESEARCH DESIGN AND METHODS Plasma apoC-I proteoforms were measured by mass spectrometry immunoassay at baseline in 4,742 nondiabetic participants in the Multi-Ethnic Study of Atherosclerosis (MESA) and 524 participants with prediabetes in the Actos Now for Prevention of Diabetes (ACT NOW) study. The primary outcome was incident diabetes (fasting glucose [FG] $7.0mmol/L or hypoglycemicmedication use in MESA; FG$7.0mmol/L or 2-h glucose $11.1 mmol/L in an oral glucose tolerance test [OGTT] in ACT NOW). Secondary outcomes were changes in FG and HOMA-IR in MESA, and OGTT-glucose area under the curve (AUCglucose) andMatsuda insulin sensitivity index (ISI) in ACT NOW. RESULTS In MESA, a higher C-I0/C-I was associated with lower risk of diabetes (n = 564 events; HR 0.87 [95% CI 0.79, 0.95] per SD; P = 0.0036; median follow-up, 9 years), and smaller increases (follow-up adjusted for baseline) in FG (20.5%; P < 0.0001) and HOMA-IR (22.9%; P = 0.011) after adjusting for baseline clinical and demographic covariates, including plasma triglycerides and HDL cholesterol. Total apoC-I concentrations were not associated with changes in FG, HOMA-IR, or incident diabetes. In ACT NOW, higher C-I0/C-I was associated with smaller increases in AUCglucose (21.8%; P = 0.0052), greater increases in ISI (7.2%; P = 0.0095), and lower risk of diabetes (n = 59 events; 0.66 [95% CI 0.48, 0.91]; P = 0.004; median follow-up, 2.5 years) after adjusting for treatment group and diabetes risk factors, including plasma lipids. CONCLUSIONS Our results indicate that apoC-I truncation may contribute to changes in glucose levels, IR, and risk of diabetes.

Original languageEnglish (US)
Pages (from-to)2214-2222
Number of pages9
JournalDiabetes Care
Volume47
Issue number12
DOIs
StatePublished - Dec 2024

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Fingerprint

Dive into the research topics of 'Relationship of Plasma Apolipoprotein C-I Truncation With Risk of Diabetes in the Multi-Ethnic Study of Atherosclerosis and the Actos Now for the Prevention of Diabetes Study'. Together they form a unique fingerprint.

Cite this